Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.

The findings from the individual study populations were consistent with the pooled data although the differences between treatment groups for TTD in FHSI-8 total scores did not reach statistical significance (ramucirumab vs placebo: REACH (AFP ≥400 ng/mL) median 2.9 vs 1.6 months; HR 0.690; 95% CI 0.470 to 1.014; p=0.054; Online supplementary figure S2A ; REACH-2 median 3.7 vs 2.8 months; HR 0.799; 95% CI 0.545 to 1.171; p=0.2382; figure 1B ).

also in 111,027 other papers